Biomea Fusion (BMEA) Non-Current Assets (2020 - 2026)
Biomea Fusion (BMEA) posted Non-Current Assets of $67000.0 for Q1 2026, down 87.16% sequentially from $522000.0 in Q4 2025, and down 99.35% YoY from $10.4 million in Q1 2025.
Biomea Fusion (BMEA) Non-Current Assets (2020 - 2026) Analysis & Trends
Biomea Fusion has reported Non-Current Assets for 7 years, with the latest figure at $67000.0 in Q1 2026.
- Quarterly Non-Current Assets fell 99.35% year-over-year to $67000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.8 million (down 74.71% YoY) and the FY2025 annual result came in at $522000.0, down 95.5% from the prior year.
- Non-Current Assets declined to $67000.0 in Q1 2026 per BMEA's latest filing, from $522000.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $23.7 million in Q1 2023 and troughed at $67000.0 in Q1 2026.
- A 5-year average of $12.8 million and a median of $11.5 million in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2026: Non-Current Assets surged 264.89% in 2023, then sank 99.35% in 2026.
- Over 5 years, Non-Current Assets stood at $11.5 million in 2022, then jumped by 80.59% to $20.7 million in 2023, then plunged by 44.06% to $11.6 million in 2024, then sank by 95.5% to $522000.0 in 2025, then slumped by 87.16% to $67000.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $67000.0, $522000.0, and $5.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | 445,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 445,000.00 |
| Mar 31, 2026 | 67,000.00 |
| Dec 31, 2025 | 522,000.00 |
| Sep 30, 2025 | 5.75 Mn |
| Jun 30, 2025 | 8.50 Mn |
| Mar 31, 2025 | 10.37 Mn |
| Dec 31, 2024 | 11.61 Mn |
| Sep 30, 2024 | 16.82 Mn |
| Jun 30, 2024 | 19.88 Mn |
| Mar 31, 2024 | 20.93 Mn |
| Dec 31, 2023 | 20.75 Mn |
| Sep 30, 2023 | 22.58 Mn |
| Jun 30, 2023 | 22.74 Mn |
| Mar 31, 2023 | 23.71 Mn |
| Dec 31, 2022 | 11.49 Mn |
| Sep 30, 2022 | 6.19 Mn |
| Jun 30, 2022 | 7.60 Mn |
| Mar 31, 2022 | 7.84 Mn |
| Dec 31, 2021 | 9.14 Mn |
| Sep 30, 2021 | 8.30 Mn |